Eyetech Inc.’s age-related macular degeneration drug may face newer, more popular competitors, but Valeant Pharmaceuticals International Inc. still believes it can wring some business out of it.
Valeant said Feb. 13 that it had agreed to acquire Palm Beach Gardens, Fla.-based Eyetech, adding Macugen (pegaptanib sodium) to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?